

Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015

October 22, 2015

LAVAL, Quebec, Oct. 22, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live webcast along with a slide presentation on Monday, October 26, 2015 at 8:00 a.m. ET (5:00 a.m. PT). The purpose of the call will be to lay out the facts including allegations made against our company regarding our relationship with Philidor and R&O, our accounting practices, and channel stuffing that contain numerous errors, unsupported speculation and incorrect interpretations of facts and circumstances to the detriment of the shareholders of the Company.

Participants on the call will include:

- Norma Provencio , Board Member, Chairman Audit and Risk Committee
- Theo Melas-Kyriazi , Board Member, Member Audit and Risk Committee
- Katharine Stevenson , Board Member, Member Audit and Risk Committee
- Howard Schiller , Board Member, former Chief Financial Officer
- Robert Hale , Board Member, Partner of ValueAct Capital
- J. Michael Pearson , Chairman and Chief Executive Officer
- Robert Chai-Onn , General Counsel
- Robert Rosiello , Chief Financial Officer
- Tanya Carro , Corporate Controller
- Ari Kellen , Company Group Chairman

"We look forward to our call on Monday where we will address and refute recent allegations," stated J. Michael Pearson , chairman and chief executive officer. stated J. Michael Pearson , chairman and chief executive officer.

The dial-in number to participate on this call is (877) 876-8393, confirmation code 67537440. International callers should dial (973) 200-3961, confirmation code 67537440. A replay will be available approximately two hours following the conclusion of the conference call to November 2, 2015, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 67537440.

The webcast and slide presentation will be hosted in the investor relations section of its corporate website at

www.valeant.com

. Participants should allow approximately five to ten minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at

www.valeant.com

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Elif McDonald
905-695-7607
elif.mcdonald@valeant.com

Media:

Renee E. Soto / Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com
/
mgavigan@sardverb.com

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-hold-investor-conference-call-on-october-26-2015-300164896.html>

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

Media inquiries

Corporate.communications@bauschhealth.com
908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**